Heidelberg University Hospital / NCT / DKFZ
Heidelberg is Germany's cancer research capital, home to the DKFZ (largest cancer research institute in Germany) and the NCT, and the birthplace of FAPI PET and the brain tumour methylation classifier.
FAPI tracers (Haberkorn, Giesel, Kratochwil), 225Ac-PSMA first-in-human, Heidelberg Ion-Beam Therapy Center (carbon ions), DKFZ methylation classifier (Pfister, von Deimling), MASTER precision oncology programme.
- FAPI PET
- Alpha PSMA therapy
- Carbon-ion therapy
- CNS methylation classifier
- DKFZ basic research
Co-created the DNA methylation classifier that changed how brain tumours are diagnosed worldwide.
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Jürgen Debus leads Europe's pioneering heavy-ion therapy centre.
Runs the NCT/DKTK MASTER programme that sequences whole genomes of rare and young-adult cancers to guide therapy.
Paediatric oncologist whose genomic work redefined childhood brain tumours into molecular subgroups.
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Pages like this
not linked directly; found by shared links- ProductFAP-2286 (177Lu / 68Ga)
Shares Uwe Haberkorn, University Hospital Düsseldorf / CIO Düsseldorf, FAPI PET, FAP.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares A university cyclotron network with shared regulatory files for new tracers, FAPI PET, FAP, Targeted alpha therapy.
- IdeaA regulatory pathway for new radiotherapy techniques modelled on drug development
Shares Jürgen Debus, Carbon-ion therapy, Core-funded radiotherapy trials infrastructure with central quality assurance.
- PersonMichael Baumann
Shares NCT/UCC Dresden – University Hospital Carl Gustav Carus, Core-funded radiotherapy trials infrastructure with central quality assurance, German Cancer Research Center (DKFZ).
- InstitutionEuropean Society for Radiotherapy and Oncology
Shares Jürgen Debus, European Association of Nuclear Medicine, Carbon-ion therapy.
- ProductActinium-225 PSMA agents
Shares Clemens Kratochwil, PSMA, Targeted alpha therapy.
- CompanyPerspective Therapeutics
Shares PSMA, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaPooled coverage-with-evidence for proton therapy across all centres
Shares Jürgen Debus, Carbon-ion therapy.